BPC-157

Preliminary Evidence

What Is BPC-157?

BPC-157, short for Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protein found in human gastric juice. First isolated and characterised by researchers at the University of Zagreb in the early 1990s, BPC-157 has attracted significant attention in the peptide research community due to its apparent protective and regenerative properties observed across numerous preclinical studies.

The peptide’s amino acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is a partial sequence of the larger body protection compound found in gastric juice. Unlike many peptides, BPC-157 demonstrates notable stability in acidic environments, which is unusual for a peptide of this size and has led researchers to investigate oral administration routes in addition to injectable forms.

It is important to note that BPC-157 is not approved by the FDA, MHRA, or most regulatory agencies for human therapeutic use. The majority of research to date has been conducted in animal models, and human clinical trial data remains extremely limited. Individuals considering BPC-157 should consult a qualified healthcare provider and understand the regulatory landscape in their jurisdiction.

Mechanism of Action

BPC-157

Angiogenesis

VEGF upregulation

May promote new blood vessel formation to deliver oxygen and nutrients to healing tissue.

Nitric Oxide System

NO homeostasis

May modulate vasodilation, blood flow, and inflammatory signalling under oxidative stress.

Growth Factors

EGF, FGF, TGF-β

May stimulate expression of growth hormone receptors and factors involved in tissue repair.

FAK-Paxillin Pathway

Cell migration

Activated in tendon fibroblast models — relevant to tendon and ligament remodelling.

Cytoprotection

Mucosal integrity

Origin in gastric juice suggests protective effects against NSAIDs, alcohol, gastric irritants.

Pathways summarised from preclinical research. Most evidence is from animal models; human mechanistic data is limited.

The mechanisms through which BPC-157 may exert its effects are not fully elucidated, but preclinical research suggests several potential pathways:

Angiogenesis and blood vessel formation. Animal studies indicate that BPC-157 may promote the formation of new blood vessels (angiogenesis) through upregulation of vascular endothelial growth factor (VEGF) and related growth factors [1]. This process is considered fundamental to tissue repair, as new blood supply delivers oxygen and nutrients necessary for healing.

Nitric oxide system modulation. Research suggests that BPC-157 may interact with the nitric oxide (NO) system, potentially influencing vasodilation, blood flow, and inflammatory signalling [2]. Studies in rat models have shown that the peptide may help maintain NO system homeostasis under conditions of oxidative stress.

Growth factor upregulation. Several animal studies indicate that BPC-157 may stimulate the expression of growth hormone receptors and various growth factors involved in tissue repair, including epidermal growth factor (EGF), fibroblast growth factor (FGF), and transforming growth factor beta (TGF-B) [3].

FAK-paxillin pathway activation. Research in tendon fibroblast models suggests that BPC-157 may activate the FAK-paxillin signalling pathway, which plays a role in cell migration and tissue remodelling — processes critical to tendon and ligament repair [4].

Cytoprotection. The peptide’s original discovery context — gastric juice — points to potential cytoprotective properties. Animal studies suggest it may help protect mucosal lining integrity and counteract damage from NSAIDs, alcohol, and other gastric irritants [5].

Research and Evidence

Gut Healing and Gastrointestinal Protection

The most extensively studied application of BPC-157 in animal models is gastrointestinal protection and healing. Multiple rodent studies have demonstrated that BPC-157 may accelerate healing of various gastrointestinal lesions, including gastric ulcers, inflammatory bowel disease models, and oesophageal damage [5][6].

Studies indicate that orally administered BPC-157 may counteract gut damage induced by NSAIDs such as ibuprofen and diclofenac in rat models. Research by Sikiric et al. (2006) reported that BPC-157 administration appeared to protect against the formation of gastric lesions and accelerated healing of existing lesions in several animal models [5].

In inflammatory bowel disease (IBD) models, animal studies suggest that BPC-157 may reduce the severity of colitis symptoms and promote mucosal healing. However, these findings have not been replicated in controlled human clinical trials, and the translation from rodent IBD models to human inflammatory bowel disease involves significant biological differences.

Tendon and Ligament Repair

Tendon repair represents one of the most promising areas of BPC-157 research. Multiple animal studies have examined the peptide’s effects on tendon-to-bone healing and tendon transection models.

A study by Chang et al. (2011) in rats with transected Achilles tendons found that BPC-157 administration appeared to accelerate tendon healing, with treated animals showing improved biomechanical properties compared to controls [4]. The researchers proposed that this effect may be mediated through the FAK-paxillin pathway and increased fibroblast proliferation.

Subsequent studies in similar models have reported that BPC-157 may promote tendon outgrowth, improve collagen organisation, and enhance the mechanical strength of healing tendons [7]. These findings are preliminary and have not yet been validated in human clinical trials.

Wound Healing

Animal research suggests that BPC-157 may accelerate cutaneous wound healing. Studies in rat models have shown that both systemic and local application of BPC-157 may promote wound closure, increase granulation tissue formation, and enhance collagen deposition [8].

Research indicates that these effects may be partially mediated through enhanced angiogenesis at the wound site, as treated wounds in animal models demonstrated increased blood vessel density compared to controls.

Neuroprotection

Emerging animal research has explored BPC-157’s potential neuroprotective properties. Rodent studies suggest the peptide may offer some degree of protection against certain neurotoxic insults and may influence dopaminergic and serotonergic pathways [9].

Studies in rat models of traumatic brain injury and peripheral nerve damage have reported that BPC-157 administration appeared to improve functional outcomes, though the mechanisms remain poorly understood. These findings are considered highly preliminary, and no human neurological studies have been conducted with BPC-157.

Dosage and Administration

Important: The following information reflects dosages reported in research literature and community protocols. BPC-157 is not an approved medication, and no official dosing guidelines exist. Always consult a qualified healthcare provider before considering any peptide protocol.

Common Research and Community-Reported Protocols

Dosages in the published animal research literature are typically reported in micrograms per kilogram of body weight. Community-reported human protocols, which are not clinically validated, typically reference:

• Subcutaneous injection: 200-500 mcg per day, often divided into two administrations. Injections are commonly administered near the site of injury in community protocols, though the pharmacokinetic rationale for local versus systemic injection has not been established in human studies.
• Oral administration: 250-500 mcg per day. BPC-157’s stability in gastric acid makes oral administration theoretically viable, and some animal research has used oral dosing. However, oral bioavailability in humans has not been characterised.

Reconstitution

BPC-157 is typically supplied as a lyophilised (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection. Proper sterile technique is essential. Reconstituted peptide should be stored refrigerated at 2-8 degrees Celsius and used within a reasonable timeframe as indicated by the supplier.

Cycling

Community protocols often reference cycles of 4-6 weeks, though the rationale for cycling and optimal duration have not been established through clinical research.

Side Effects and Safety

BPC-157’s safety profile in humans has not been established through controlled clinical trials. The following information is based on animal research and self-reported community experiences.

Reported in animal studies: BPC-157 has demonstrated a favourable safety profile in rodent studies, with no observed lethal dose (LD1 not reached) in toxicity studies [10]. Animal studies have not reported significant adverse effects at the doses tested.

Community-reported side effects (anecdotal, not clinically validated):

• Mild nausea, particularly with oral administration
• Lightheadedness or dizziness
• Injection site discomfort, redness, or minor bruising
• Headache
• Fatigue

Potential concerns and unknowns:

• The long-term safety of BPC-157 in humans has not been studied
• The peptide’s effects on angiogenesis raise theoretical concerns regarding individuals with active malignancies or a history of cancer, as enhanced blood vessel formation could theoretically support tumour growth
• Interactions with medications have not been characterised
• Effects during pregnancy and lactation are unknown and the peptide should be avoided in these populations
• Individuals with active cancer or a predisposition to cancer should exercise particular caution and consult their oncologist

Frequently Asked Questions

Is BPC-157 legal?

The legal status of BPC-157 varies by jurisdiction. In the United States, it exists in a regulatory grey area — it is not FDA-approved for human use but is available as a research chemical. In Australia, it may be available through compounding pharmacies with a valid prescription. In the United Kingdom, it is not licensed by the MHRA. BPC-157 is prohibited by WADA under the S0 Non-Approved Substances category. Always check your local regulations before considering BPC-157.

How is BPC-157 different from TB-500?

While both BPC-157 and TB-500 are studied for their potential roles in tissue repair and recovery, they operate through different mechanisms. BPC-157 research focuses primarily on angiogenesis, the NO system, and growth factor modulation, while TB-500 (a fragment of Thymosin Beta-4) research centres on actin regulation and cell migration. Some community protocols combine both peptides, though no clinical research has evaluated this combination.

Can BPC-157 be taken orally?

BPC-157 is notably stable in gastric acid, which is unusual for a peptide. Animal research has used oral administration routes, and some community protocols report oral dosing. However, the oral bioavailability of BPC-157 in humans has not been quantified through pharmacokinetic studies. Subcutaneous injection is the most commonly referenced route in both research and community protocols.

How long does it take for BPC-157 to work?

Timeframes reported in animal studies vary depending on the injury model. Community reports (which are anecdotal and not clinically validated) typically reference effects within 1-2 weeks, with more substantial outcomes observed over 4-6 week periods. Individual responses may vary significantly.

Is BPC-157 safe?

The long-term safety profile of BPC-157 in humans has not been established. While animal studies have not identified significant toxicity at the doses tested, the absence of controlled human trials means that safety cannot be confirmed. Anyone considering BPC-157 should consult a qualified healthcare professional and be aware of the current limitations of the evidence base.

References

References

1. Seiwerth S, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1014-1025.
2. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857-865.
3. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014;20(7):1126-1135.
4. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
5. Sikiric P, et al. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999;7(1):1-14.
6. Sikiric P, et al. Pentadecapeptide BPC 157 and its effects on a NSAID cyclooxygenase system. Journal of Physiology Paris. 2003;97(4-6):461-466.
7. Staresinic M, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. 2006;24(5):1109-1117.
8. Seiwerth S, et al. BPC 157 and wound healing. Current Pharmaceutical Design. 2018;24(18):2009-2017.
9. Sikiric P, et al. Pentadecapeptide BPC 157 interactions with dopamine and serotonin systems. Current Neuropharmacology. 2021;19(10):1696-1713.
10. Sikiric P, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013;19(1):76-83.

Continue Reading

Readers also explore

All peptides →

Recovery & Healing

TB-500

Thymosin Beta-4 Fragment

tissue repair · inflammation reduction · cardiac repair

Open profile

Anti-Aging

GHK-Cu

Copper Peptide GHK-Cu

skin rejuvenation · wound healing · anti-aging

Open profile